Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H16N4O4 |
Molecular Weight | 400.3868 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C2=CC=C(C=C12)[N+]([O-])=O)C3=C(C(=O)NC3=O)C4=CN(C)C5=C4C=CC=C5
InChI
InChIKey=OVSKGTONMLKNPZ-UHFFFAOYSA-N
InChI=1S/C22H16N4O4/c1-24-10-15(13-5-3-4-6-17(13)24)19-20(22(28)23-21(19)27)16-11-25(2)18-9-12(26(29)30)7-8-14(16)18/h3-11H,1-2H3,(H,23,27,28)
Molecular Formula | C22H16N4O4 |
Molecular Weight | 400.3868 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. MKC-1 has shown broad antitumor activity in preclinical models. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus. MKC-1 had been in phase II clinical trials for the treatment of ovarian cancer, endometrial cancer, pancreatic cancer and breast cancer.
This compound was originally discovered by Roche, then licensed to EntreMed (now CASI Pharmaceuticals) the exclusive worldwide rights to develop and commercialize. However, no recent development has been reported.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095217 |
|||
Target ID: CHEMBL2095189 |
|||
Target ID: CHEMBL2363074 |
|||
Target ID: CHEMBL1974 |
|||
Target ID: CHEMBL3604 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1732526 |
1.1 µM [IC50] | ||
Target ID: CHEMBL2095182 |
|||
Target ID: map04150 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
19.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
23.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
MKC-1 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
24.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
280 mg/m² 2 times / day multiple, oral dose: 280 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-4006 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
400 mg/m² 2 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
800 mg/m² 1 times / day multiple, oral dose: 800 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15310782 |
560 mg/m² 1 times / day multiple, oral dose: 560 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: |
RO 27-0431 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21800081
Cancer: MKC-1 was administered orally, twice daily, initially at 100 mg/m(2) dosing for 14 consecutive days of a 28-day cycle. This schedule was modified during the trial to fixed and continuous dosing of 150 mg per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:51:56 GMT 2023
by
admin
on
Fri Dec 15 15:51:56 GMT 2023
|
Record UNII |
DNZ11VPY7Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C25974
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C2507
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY | |||
|
5327686
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY | |||
|
125313-92-0
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY | |||
|
DTXSID60154735
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY | |||
|
DNZ11VPY7Q
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY | |||
|
100000175612
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY | |||
|
DB05608
Created by
admin on Fri Dec 15 15:51:56 GMT 2023 , Edited by admin on Fri Dec 15 15:51:56 GMT 2023
|
PRIMARY |